Articles

Videos

Podcasts

Clinical Role

Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series.

Risk of Infection Increases with Longer Duration of Bispecific Antibody Therapy in Multiple Myeloma

New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.

New Tool Developed to Track How Breast Cancer Grows

Analysis shows that the therapy is associated with a reduced acute toxicity burden associated with intensity-modulated radiation therapy.

Curative-Intent Radiotherapy, IMPT Show More Benefits for Oropharyngeal Carcinoma

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

DNA May Age More Quickly in Patients With Cancer Who Are HIV-positive 

Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.

Ponatinib Produces Higher Rates of Minimal Residual Disease-Negative Complete Remission in Ph+ ALL

Sugar…may not always be sweet. Survivors of childhood cancer have a risk of accelerated aging with every 25 grams of sugar consumed, according to researchers.

Diet High in Sugar May Accelerate Aging in Survivors of Childhood Cancer 

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

Study: FGFR mRNA Overexpression Occurs Frequently for Those With Cholangiocarcinoma

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer Treatment

GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.

Novel Treatment Shows Promising Antitumor Activity Against HER2+ Cancers

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen  therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.